Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris
DOI:
https://doi.org/10.2340/actadv.v102.1289Keywords:
Bullous pemphigoid, pityriasis rubra pilaris, BP180, LAD-1, intravenous immunoglobulinAbstract
Abstract is missing (Short communication)
Downloads
References
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
https://doi.org/10.1016/S0140-6736(12)61140-4
Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.
https://doi.org/10.1007/s12016-017-8633-4
Chaudhary R, Chaudhary N. A 45-year-old woman with erythroderma and bullous eruption: erythrodermic bullous pemphigoid. J Pharm Biomed Sci 2018; 8: 94-97.
Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol 2019; 44: 73-75.
https://doi.org/10.1111/ced.13718
Miyashita K, Iioka H, Miyagawa F, Ishii N, Hashimoto T, Asada H. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. Eur J Dermatol 2018: 28: 248-250.
https://doi.org/10.1684/ejd.2018.3229
Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015; 135: 1445-1447.
https://doi.org/10.1038/jid.2014.547
Goto-Hamano H, Ito K, Sakamoto-Kumura K, Terui T, Ohyama B, Hashimoto T, Hara H. Autoantibodies against multiple epitopes in Bp180 and laminin gamma-1 in subepidermal blistering skin disease associated with psoriatic erythroderma. Indian J Dermatol 2015; 60: 521.
https://doi.org/10.4103/0019-5154.164433
Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol 1999; 9: 537-539.
Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol 2007; 156: 1055-1056.
https://doi.org/10.1111/j.1365-2133.2007.07773.x
Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in skin autoimmune disease. Front Immunol 2019; 10: 1090.
https://doi.org/10.3389/fimmu.2019.01090
Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017; 77: 845-854.e5.
https://doi.org/10.1016/j.jaad.2017.07.013
Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-854.
Published
How to Cite
License
Copyright (c) 2022 Irina Gasslitter, Judith Löffler-Ragg, Enno Schmidt, Matthias Schmuth, Robert Gruber

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.